Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer

A quality of life (QoL) analysis of the RESPECT trial (n=275) found addition of adjuvant chemotherapy to trastuzumab had significant detrimental effects on global QoL, morale, and activity capacity which lasted for at least 12 months but were not observed at 36 months.

Journal of Clinical Oncology